



**THE FOUNDATION  
FOR SECURE  
MARKETS®**

#58435

**Date:** February 26, 2026

**Subject:** Avidity Biosciences, Inc. - Distribution  
Option Symbol: RNAM  
New Symbol: RNA1  
Date: 02/27/2026  
\* \* \* Update \* \* \*

On February 23, 2026, Avidity Biosciences, Inc. (“RNA,” changing to “RNAM” effective February 26, 2026) adjourned its special meeting to February 26, 2026, per the Supplement to the Proxy Statement for the Special Meeting filed February 23, 2026 (“Supplement”). At the special meeting, shareholders voted concerning i) the Agreement and Plan of Merger with Ajax Acquisition Sub, Inc., a wholly owned subsidiary of Novartis AG, and Novartis AG, and ii) the Separation and Distribution Agreement among RNA, Novartis AG, and Bryce Therapeutics, Inc., a wholly owned subsidiary of RNA which has since changed its name to Atrium Therapeutics, Inc. (“SpinCo”).

The Separation and Distribution Agreement has been approved. Avidity will separate effect a pre-closing reorganization and transfer certain assets to SpinCo in the Separation transaction (“Separation”) as described in the Avidity Proxy Statement dated January 30, 2026 (“Proxy”). The previous OCC Information Memo (#58372) discussed the possibility of an asset sale to a party identified as the ROFN holder in the Proxy. The negotiation period has expired, and the asset sale will not take place.

Following the Separation, Avidity will distribute 1 share of SpinCo for every 10 shares of Avidity held (“the Distribution”). **The Distribution has been approved by Avidity Biosciences, Inc. shareholders and will occur on February 27, 2026.** Per the Supplement, the effective date of the Merger is expected to occur on February 27, 2026.

**The RNA symbol will be recycled to the Common Shares of Atrium Therapeutics, Inc. which will be listed on the NASDAQ Global Market on February 27, 2026.**

**Contract Adjustment**

**Date:** February 27, 2026

**Option Symbol:** RNAM changes to RNA1

**Strike Divisor:** 1

**Contracts Multiplier:** 1

**New Multiplier:** 100 (e.g., a premium of 1.50 yields \$150; a strike of 45 yields \$4,500.00)

**New Deliverable Per Contract:**  
1) 100 Avidity Biosciences, Inc. (RNAM) Common Shares  
2) 10 Atrium Therapeutics, Inc. (RNA) Common Shares

**Settlement Allocation:**  
RNAM: 95%  
RNA: 5%

**CUSIPs:**  
RNAM: 05370A108  
(New) RNA: 04965N104

### Pricing

The underlying price for RNA1 will be determined as follows:

$$\text{RNA1} = \text{RNAM} + 0.10 (\text{RNA})$$

### Disclaimer

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and futures and the nature of any adjustment is made by OCC pursuant to Chapter 28 (XXVIII) of OCC's Rules. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

**ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.**

For questions regarding this memo, please email the Investor Education team at [options@theocc.com](mailto:options@theocc.com). Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email [memberservices@theocc.com](mailto:memberservices@theocc.com).